Fibrotic processes are the underlying factors in a variety of difficult-to-treat diseases, resulting in progressive organ failure. For most fibrotic diseases, blocking inflammatory events only, e.g. by inhibiting cytokine signaling, is not expected to deliver substantial disease stabilization or reversal. Because fibrosis is such a complex and interconnected process, one needs to identify assets with broad modes of action able to address redundancy across multiple pathways.

Growth factor pathways coordinate broad morphogenic and tissue repair programs, and can be leveraged to profoundly alleviate tissue injury, fibrotic remodeling, and organ failure. Because growth factors possess such broad activity, it is important to have a deep understanding about how to modulate them, and how to design small molecules or antibodies to do this.

This is where we leverage our deep understanding of growth factor biology and employ smart small molecules inhibiting the TGFβ pathway and agonistic antibodies stimulating the HGF/MET pathway. Our pipeline consists of unique assets with a novel mode of action against well-validated and potentially disease-modifying targets with the aim to repair tissue injury, resolve fibrosis and restore organ function in patients with high unmet medical need.